etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin + rituximab + lenalidomide

**Etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin + rituximab + lenalidomide** is a multi-agent combination regimen primarily used in the treatment of aggressive B-cell non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma. It integrates **R-CHOP** (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), a standard immunochemotherapy backbone that targets CD20-positive B cells via rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), with added **etoposide** (a topoisomerase II inhibitor causing DNA damage) and **lenalidomide** (an immunomodulatory agent that enhances NK and T-cell activity, cereblon-dependent degradation of transcription factors, and anti-angiogenic effects). This intensified regimen aims to improve outcomes in high-risk or relapsed settings by combining cytotoxic chemotherapy, monoclonal antibody targeting, and immune modulation, though specific trials for this exact seven-drug combination are limited, with components studied separately in follicular lymphoma (FL) and DLBCL.